AbCellera Biologics (ABCL) said it will release top-line results from its Phase 2 trial of ABCL635 for moderate-to-severe vasomotor symptoms (hot flashes) due to menopause. The update is a potential near-term catalyst, but the article provides no efficacy/safety results or magnitude yet.
AbCellera Biologics (ABCL) said it will release top-line results from its Phase 2 trial of ABCL635 for moderate-to-severe vasomotor symptoms (hot flashes) due to menopause. The update is a potential near-term catalyst, but the article provides no efficacy/safety results or magnitude yet.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.10
Ticker Sentiment
